CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 94 enrolled
Drug / intervention
Omidriadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03864133
NCT03864133Phase 4Completed
CompareCT.gov

The Effects of Intraocular Phenylephrine/Ketorolac Infusion on Retinal Thickness and Macular Edema in Cataract Surgery

Wake Forest University Health Sciences·interventional·Posted Mar 6, 2019·Updated Nov 30, 2023

In Brief

A Phase 4 clinical trial evaluating Omidria for Cataract. Completed, enrolled 94 participants across 1 site.

Detailed Summary

This study evaluates the effect of Intraocular Phenylephrine/Ketorolac Infusion on Retinal Thickness and Macular Edema in Cataract Surgery. Participants will receive infusions of Phenylephrine/Ketorolac during surgery instead of receiving topical NSAID drops pre and post operatively.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesUnited States
CollaboratorsOmeros Corporation

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedMar 6, 2019
Enrollment StartJul 8, 2019
Primary CompletionJun 30, 2021
Study CompletionAug 16, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.3 years ago

Interventions

Omidriadrug

Phenylephrine and Ketorolac infusion of 1%/0.3% during cataract surgery.